Influenza virus extraction diluent and application thereof
Through improved influenza virus dilution formulations, including Na2HPO4·12H2O, NaH2PO4·2H2O, NaCl, Proclin300, ethylenediaminetetraacetic acid disodium dihydrate, polyoxyethylene-8-octylphenyl ether and alkylphenol poly Oxygen ether solves the problem of insufficient virus extraction ability of existing diluents in nasopharyngeal swabs, improves detection accuracy and product stability, is suitable for on-site detection, has a short color development time, and is suitable for large-scale applications.
Patent Information
- Application Number
- CN202411568174.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-11-05
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2044-11-05
AI Technical Summary
The existing influenza virus sample dilutions have insufficient ability to extract viruses in nasopharyngeal swabs, resulting in inaccurate test results, poor stability of in vitro diagnostic reagents, and short shelf life of the product, which cannot meet the needs of certain testing occasions.
The diluent formula includes Na2HPO4·12H2O, NaH2PO4·2H2O, NaCl, Proclin300, ethylenediaminetetraacetic acid disodium dihydrate, polyoxyethylene-8-octylphenyl ether and alkylphenol polyoxyethylene ether to improve The extraction capability and product stability are enhanced, and the accuracy and suitability of detection are enhanced.
It improves the extraction capacity and product stability of influenza viruses, extends the service life, reduces costs and detection time, is suitable for on-site testing, has a short color development time, and does not require expensive instruments and equipment, and is suitable for large-scale testing.
Smart Images

Figure CN119086896A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of biological products, and in particular relates to an influenza virus extraction diluent and an application thereof. Background Art
[0002] Influenza virus is the pathogen of influenza. There are three main detection methods, namely viral nucleic acid detection, virus isolation, and antigen detection.
[0003] 1. Virus nucleic acid test: collect throat swabs, nasal swabs, sputum, etc., and detect whether there is influenza virus RNA through polymerase chain reaction. If the nucleic acid test is positive, influenza can be diagnosed and the type of pathogen can be determined; 2. Virus isolation: Virus isolation is the gold standard for diagnosing influenza. If influenza virus is isolated from nasopharyngeal secretions, influenza can be diagnosed. 3. Antigen testing: Antigen testing is a commonly used rapid influenza virus testing method. Its accuracy is lower than that of nucleic acid testing. If the antigen is positive, influenza can be diagnosed.
[0004] Antigen detection often uses colloidal gold-labeled immunochromatography, which is a new detection technology that has emerged and developed rapidly in recent years. It is quick and simple to operate during sample extraction and testing, takes a short time, and produces relatively accurate results. It is low-cost, pollution-free, and does not require training. It is less affected by human factors and is more suitable for on-site testing than traditional methods, and is suitable for large-scale testing.
[0005] When extracting samples, it is usually necessary to add sample extraction diluent. Common sample diluent formulas are: PBS (phosphate buffered saline) is a commonly used sample diluent. It is usually mixed with potassium dihydrogen phosphate, disodium hydrogen phosphate, sodium chloride and potassium chloride, and the pH value is adjusted to 7.2-7.4 to prepare a sample diluent. BSA (bovine serum albumin) may be added to increase stability. Tris buffer, the main component of which is trishydroxymethylaminomethane, is usually reacted with hydrochloric acid to adjust the pH value and is used to maintain the pH stability of the solution. Physiological saline composed of an appropriate concentration of sodium chloride (Nacl). Other ingredients include glucose, urea, etc., which are used to improve the recovery rate of high-concentration samples, solve the problem that high-concentration samples cannot be accurately determined, and reduce research and development costs. However, conventional diluents are not effective in extracting viruses from nasopharyngeal swabs. In some testing occasions, commonly used sample diluents cannot meet the test requirements. The concentration of the treated samples is low, and the colloidal gold test results are not strong, which affects the accuracy of the test results. In addition, most of the current in vitro diagnostic reagents have poor stability and a short shelf life. Summary of the invention
[0006] In order to solve one of the above problems, the present invention provides an influenza virus extraction diluent and application thereof.
[0007] In order to achieve the above object, the present invention adopts the following technical means: The first aspect of the present invention provides an influenza virus extraction diluent, which comprises Na2HPO4·12H2O, NaH2PO4·2H2O, NaCl, Proclin300, disodium ethylenediaminetetraacetic acid dihydrate, polyoxyethylene-8-octylphenyl ether, and alkylphenol polyoxyethylene ether.
[0008] In some embodiments of the present invention, in the diluent, Na2HPO4·12H2O 2.5-3 g / L; NaH2PO4·2H2O 0.2-0.3 g / L; NaCl 8.5-9.5 g / L; Proclin300 200 μL / L; ethylenediaminetetraacetic acid disodium salt dihydrate 1-1.2 g / L; polyoxyethylene-8-octylphenyl ether 2.5-3.5%; and alkylphenol polyoxyethylene ether 0.5-1.5%.
[0009] In some embodiments of the present invention, preferably, in the diluent, polyoxyethylene-8-octylphenyl ether is 3%; and alkylphenol polyoxyethylene ether is 1%.
[0010] Further preferably, the substances and concentrations in the diluent are: Na2HPO4·12H2O 2.8 g / L; NaH2PO4·2H2O 0.24 g / L; Nacl 9.1 g / L; Proclin300 200 μL / L; ethylenediaminetetraacetic acid disodium salt dihydrate 1.114 g / L; polyoxyethylene-8-octylphenyl ether 3%; alkylphenol polyoxyethylene ether 1%.
[0011] The second aspect of the present invention provides use of the influenza virus extraction diluent described in the first aspect in the preparation of products related to influenza virus extraction and detection.
[0012] In some embodiments of the present invention, the influenza virus includes influenza A virus and influenza B virus.
[0013] In some embodiments of the present invention, products related to influenza virus detection include, but are not limited to, extraction reagents and kits.
[0014] The third aspect of the present invention provides a kit for influenza virus detection, comprising the influenza virus extraction dilution solution described in the first aspect.
[0015] The fourth aspect of the present invention provides a method for detecting influenza virus using a colloidal gold detection reagent strip, comprising the following steps: (1) Fully extracting the biological sample using the influenza virus extraction diluent described in the first aspect; (2) Vertically drip the extracted liquid in step (1) onto the sample pad of the colloidal gold test strip and leave it at room temperature for 5-10 minutes before determining the test result.
[0016] In some embodiments of the present invention, the biological sample is a nasopharyngeal secretion sample, an oropharyngeal secretion sample, or other body fluid samples.
[0017] Beneficial effects of the present invention Compared with the prior art, the present invention has the following beneficial effects: The present invention provides an influenza virus extraction diluent and its application. Adding a substance polyoxyethylene-8-octylphenyl ether and alkylphenol polyoxyethylene ether to the diluent not only improves the extraction capacity but also enhances the stability of product performance: the accelerated stability test is performed at 45°C for 35 days, and the results are good, and there is no significant difference in performance with 0 days. It saves costs and time, and also provides reference value for other products. For customers, the product life is extended, the limitations are reduced, the temperature suitability is higher, and the market value is greater. It is easy to operate and suitable as a conventional detection method.
[0018] The diluent is used in the colloidal gold-labeled immunoassay to detect influenza virus. It is pollution-free, does not require training, has a short color development time, is convenient and fast, and can detect whether the biological sample contains influenza antigens in a relatively short time. It does not require expensive instruments and equipment, is suitable for on-site testing, and has broad market prospects and application value. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 The machine-readable and colorimetric standard diagrams of the test results of the present invention are shown; Figure 2 The comparison of T1 value results obtained from the 0-35 day test under the accelerated conditions of 45°C for the old formulation is shown; Figure 3 The comparison of T1 value results obtained from the 0-35 day test of the new formulation under 45°C accelerated conditions is shown; Figure 4 The comparison of T2 value results obtained from the 0-35 day test under the accelerated conditions of 45°C for the old formulation is shown; Figure 5 The comparison of T2 values obtained from the new formulation under accelerated conditions of 45°C for 0-35 days is shown. DETAILED DESCRIPTION
[0020] The following examples are used to demonstrate preferred embodiments of the present invention. It will be appreciated by those skilled in the art that the techniques disclosed in the following examples represent techniques discovered by the inventors that can be used to implement the present invention and therefore can be considered as preferred embodiments of the present invention. However, it will be appreciated by those skilled in the art based on this specification that many modifications may be made to the specific embodiments disclosed herein and still achieve the same or similar results without departing from the spirit or scope of the present invention.
[0021] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs, and the materials cited herein and those cited by them are incorporated by reference. Those skilled in the art will recognize or will learn through routine experimentation that there are many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the claims.
[0022] The technical solution of this patent is further described in detail below in conjunction with specific implementation methods.
[0023] Preparation: 1. Prepare diluent: (1) The old formula before improvement: Na2HPO4·12H2O 3 g / L; NaH2PO4·2H2O 0.528 g / L; Nacl 12.8 g / L; Proclin 300 200 μL / L; ethylenediaminetetraacetic acid disodium salt dihydrate 1.234 g / L.
[0024] (2) Improved new formula: Na2HPO4·12H2O 2.8 g / L; NaH2PO4·2H2O 0.24 g / L; Nacl 9.1 g / L; Proclin 300 200 μL / L; ethylenediaminetetraacetic acid disodium salt dihydrate 1.114 g / L; polyoxyethylene-8-octylphenyl ether 3%; alkylphenol polyoxyethylene ether 1%.
[0025] (3) According to the old formula before improvement and the new formula after improvement, calculate the amount of each component according to the preparation volume of 50 mL of diluent, pour the above substances into purified water in turn, stir to dissolve and make up the volume; Put the fully dissolved diluted solution into a clean centrifuge tube or container and seal it.
[0026] (4) Divide the prepared diluent into sampling tubes, with each tube containing 500 μL, and wait for use.
[0027] 2. Preparation of colloidal gold test strips 1. Preparation of gold label pad: Take 100mL of colloidal gold solution and put it into a beaker. Stir and add 0.2M K2CO3 to adjust the pH of the gold water to 9.5. After stirring, add 1 mg of influenza A antibody and stir at room temperature for 15 min. Add 1mL of 10% BSA solution to block nonspecific adsorption sites. Stir at room temperature for 15min and centrifuge at 10000rpm for 20min. Discard the supernatant and take the precipitate and dilute it to 1mL with gold label diluent (Tris 2.5g / L, casein 2.5g / L, 0.03% Proclin300) for later use. The same method was used to label influenza B antibody and mouse IgG used in the C-line system.
[0028] After mixing the labeled influenza A antibodies and influenza B antibodies, they were evenly sprayed on the glass fiber using a gold sprayer. After drying overnight, the preparation of the gold-labeled pad was completed.
[0029] 2. Preparation of nitrocellulose membrane Dilute another influenza A antibody with spotting diluent (2.9g / L Na2HPO4.12H2O, 0.282g / L NaH2PO4.2H2O, 8.775g / L Nacl, 200μL / L Proclin300) and spot it on the nitrocellulose membrane using a spotting instrument to form the T1 line. Use the same method to spot another influenza B antibody as the T2 line and goat anti-mouse IgG as the C line.
[0030] 3. Assemble the prepared gold label pad, nitrocellulose membrane, absorbent filter paper, sample pad, card shell, etc. into a colloidal gold reagent strip for influenza virus detection.
[0031] 3. The criteria for colloidal gold detection are as follows: ① Negative: Only one band appears on the quality control line, and no band appears in the test area, which is negative; ②T1 positive: two colored reaction lines appear, one in the C area (quality control area) and the other in the T1 area; T2 positive: two colored reaction lines appear, one in the C area (quality control area) and one in the T2 area; T1 / T2 positive: Three colored reaction lines appear, one in area C (quality control area), one in area T1, and one in area T2.
[0032] ③ Invalid: No strip appears on the quality control line, indicating that the test strip is damaged and a new test strip should be replaced and retested.
[0033] The colloidal gold immunoassay analyzer is used to read the values. The color card line intensity displays G1-G10. The relationship between the machine-readable value range and the color card line intensity is as follows: Figure 1 As shown, T1 represents the intensity of influenza A test results, and T2 represents the intensity of influenza B test results. The larger the value, the stronger the color development and positive value.
[0034] The judgment method of color card reading and machine reading is shown in Table 1 below.
[0035] Table 1 Judgment method of color card reading and machine reading
[0036] Example 1 Accelerated test at 45°C in dilution solution 1. Dilution 0-day colloidal gold method detection 1. Preparation of sample test solution: Place swabs with different virus concentrations into sampling tubes with the newly prepared and packaged diluents, fully extract and stir, then take out the swabs. The liquid in the sampling tube is the sample test solution.
[0037] 2. Colloidal gold method to detect the effect of diluent: vertically add 3-5 drops of sample test solution to the sample pad of the prepared colloidal gold test reagent strip (repeat the test 3 times for each concentration), and after leaving it at room temperature for 10 minutes, determine the test results as shown in Table 2.
[0038] Table 2 Detection results of colloidal gold method for dilution on day 0
[0039] 2. 7-day colloidal gold test of diluted solution 1. Preparation of sample test solution: Place swabs with different virus concentrations into sampling tubes containing diluent that has been configured and packaged and stored at 45°C for 7 days. After fully extracting and stirring, take out the swabs. The liquid in the sampling tube is the sample test solution.
[0040] 2. Colloidal gold method to detect the effect of diluent: vertically add 3-5 drops of sample detection liquid to the sample pad of the prepared colloidal gold detection reagent strip, and place it at room temperature for 10 minutes to determine the test results as shown in Table 3.
[0041] Table 3 7-day colloidal gold test results of dilution solution
[0042] 3. 14-day colloidal gold test of dilution solution 1. Preparation of sample test solution: Place swabs with different virus concentrations into sampling tubes containing diluent that has been configured and packaged and stored at 45°C for 14 days. After fully extracting and stirring, take out the swabs. The liquid in the sampling tube is the sample test solution.
[0043] 2. Colloidal gold method to detect the effect of diluent: vertically add 3-5 drops of sample detection liquid to the sample pad of the prepared colloidal gold detection reagent strip, and place it at room temperature for 10 minutes. The test results are shown in Table 4.
[0044] Table 4 14-day colloidal gold test results of dilution solution
[0045] 4. 21-day colloidal gold test of diluted solution 1. Preparation of sample test solution: Place swabs with different virus concentrations into sampling tubes containing diluent that has been configured and packaged and stored at 45°C for 21 days. After fully extracting and stirring, take out the swabs. The liquid in the sampling tube is the sample test solution.
[0046] 2. Colloidal gold method to detect the effect of diluent: vertically add 3-5 drops of sample detection liquid to the sample pad of the prepared colloidal gold detection reagent strip, and place it at room temperature for 10 minutes. The test results are shown in Table 5.
[0047] Table 5 Detection results of colloidal gold method for dilution solution at 21 days
[0048] 5. 28-day colloidal gold test of diluted solution 1. Preparation of sample test solution: Place swabs with different virus concentrations into sampling tubes containing diluent that has been configured and packaged and stored at 45°C for 28 days. After fully extracting and stirring, take out the swabs. The liquid in the sampling tube is the sample test solution.
[0049] 2. Colloidal gold method to detect the effect of diluent: vertically add 3-5 drops of sample detection liquid to the sample pad of the prepared colloidal gold detection reagent strip, and place it at room temperature for 10 minutes. The test results are shown in Table 6.
[0050] Table 6 28-day colloidal gold test results of dilution
[0051] 6. 35-day colloidal gold test of diluted solution 1. Preparation of sample test solution: Place swabs with different virus concentrations into sampling tubes containing diluent that has been configured and packaged and stored at 45°C for 35 days. After fully extracting and stirring, take out the swabs. The liquid in the sampling tube is the sample test solution.
[0052] 2. Colloidal gold method to detect the effect of diluent: vertically add 3-5 drops of sample detection liquid to the sample pad of the prepared colloidal gold detection reagent strip, and place it at room temperature for 10 minutes. Determine the test results as shown in Table 7.
[0053] Table 7 35-day colloidal gold test results of dilution solution
[0054] The data of Examples 1 to 6 are compared by average as follows: The average T1 data of the old formula and the new formula are shown in Tables 8, 9 and Figure 2 and Figure 3 The average T2 values of the old and new formulas are shown in Tables 10, 11 and Figure 4 and Figure 5 shown.
[0055] Table 8 T1 average data of old formula
[0056] Table 9 New formula T1 average data
[0057] Table 10 T2 average data of old formula
[0058] Table 11 T2 average data of the new formula
[0059] At the same time, we also used the company's quality control products to test the detection rate. The performance comparison results between the old formula and the new formula are shown in Table 12 below. The detection rate is the result of testing 100 copies of the company's quality control products.
[0060] Table 12 Performance comparison between old formula and new formula
[0061] The overall results show that the old formula was accelerated at 45°C, and the average T1 and T2 values from 7 to 14 days dropped sharply, indicating instability. However, the new formula was accelerated at 45°C, and the average T1 and T2 values from 0 to 35 days were not significantly different from the results of 0 day, showing the stability of the product performance. This stability has led to an extension of the service life.
[0062] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as references separately. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined in the present application.
Claims
1. An influenza virus extract diluent, Features: The diluent includes Na 2 HPO 4 12H 2 O, NaH 2 PO 4 ·2H 2 O, NaCl, Proclin300, ethylenediaminetetraacetic acid disodium salt dihydrate, polyoxyethylene-8-octylphenyl ether, alkylphenol polyoxyethylene ether.
2. An influenza virus extraction diluent according to claim 1, Features: In the diluent, Na 2 HPO 4 12H 2 O 2.5-3g / L; NaH 2 PO 4 ·2H 2 O 0.2-0.3g / L; NaCl 8.5-9.5g / L; Proclin300 200μL / L; ethylenediaminetetraacetic acid disodium salt dihydrate 1-1.2g / L; polyoxyethylene-8-octylphenyl ether 2.5-3.5%; alkylphenol polyoxyethylene ether 0.5-1.5%.
3. An influenza virus extraction diluent according to claim 2, Features: In the diluent, polyoxyethylene-8-octylphenyl ether is 3%; alkylphenol polyoxyethylene ether is 1%.
4. Use of the influenza virus extraction diluent according to any one of claims 1 to 3 in the preparation of products related to influenza virus extraction and detection.
5. The use according to claim 4, Features: The influenza virus includes influenza A virus and influenza B virus.
6. The use according to claim 4, Features: Products related to influenza virus detection include extraction reagents and test kits.
7. A kit for extracting and detecting influenza viruses, Features: The invention comprises the influenza virus extract diluent according to any one of claims 1 to 3.
8. A method for detecting influenza virus using a colloidal gold test strip, Features: The following steps are included: (1) Fully extracting a biological sample using the influenza virus extraction diluent according to any one of claims 1 to 3; (2) Vertically drip the extracted liquid in step (1) onto the sample pad of the colloidal gold test strip and leave it at room temperature for 5-10 minutes before determining the test result.
9. The method according to claim 8, Features: The biological samples are nasopharyngeal secretion samples and oropharyngeal secretion samples.
Citation Information
Patent Citations
Sample pad processing liquid, H7 subtype avian influenza virus colloidal gold test strip and preparation method thereof
CN104251908A
Reagent for lipid typing detection
CN107561297A
Method for preparing type A universal and H7N9 subtype influenza virus colloidal gold joint detection test paper
CN109142725A
Influenza virus and 2019 novel coronavirus antibody combined detection device and preparation method thereof
CN111579792A
Sample pad treating fluid for detecting respiratory viruses and application of sample pad treating fluid
CN117233381A
